论文部分内容阅读
目的:评价奥沙利铂(OXA)联合亚叶酸钙(LV)和氟尿嘧啶(5-Fu)方案治疗国人晚期胃癌的近期疗效和毒性反应。方法: 28例晚期胃癌,给予FOLFOX改良方案,即OXA120mg/m、静脉滴注4小时,LV200mg、静脉滴注2小时, 5-Fu500mg于LV滴完后静脉推注, 5-Fu3.0g持续静脉滴注46小时,每3周重复。按WHO标准评价近期疗效和毒性反应;同时观察TTP和MST。结果:可评价疗效者26例,获得PR11例(42.31% ),SD11例(42.31% ),PD4例(15.38% ),总有效率(CR+PR)为42.31%。中位TTP5 6个月,MST9个月。主要毒性反应为恶心、呕吐、骨髓抑制及一过性感觉异常,全组无治疗相关性死亡。结论:OXA联合LV/5-Fu组成的FOLFOX改良方案治疗晚期胃癌患者有效,临床缓解率较高,不良反应轻,可以耐受。
Objective: To evaluate the short-term effects and toxicities of oxaliplatin (OXA) in combination with leucovorin (LV) and 5-fluorouracil (5-Fu) in the treatment of advanced gastric cancer in Chinese population. Methods: 28 cases of advanced gastric cancer were given FOLFOX modified program, namely OXA120mg / m, intravenous infusion of 4 hours, LV200mg, intravenous infusion of 2 hours, 5-Fu500mg intravenous drip after LV injection, 5-Fu3.0g continuous vein Instillation 46 hours, repeated every 3 weeks. According to the WHO standard evaluation of the recent efficacy and toxicity; simultaneous observation of TTP and MST. Results: Among the 26 evaluable patients, 11 were PR11 (42.31%), SD11 (42.31%), PD4 (15.38%) and the total effective rate was 42.31%. Median TTP5 6 months, MST 9 months. The main toxic reactions were nausea, vomiting, myelosuppression and transient sensory abnormalities, with no treatment-related deaths in the entire group. Conclusion: The modified FOLFOX combined with OXA and LV / 5-Fu is effective in treating patients with advanced gastric cancer. The clinical remission rate is high, the adverse reactions are mild and can be tolerated.